Table 2.
Brain scores | Behavior scores | |||
---|---|---|---|---|
r/t | p | r/t | p | |
Disease severity | ||||
Disease duration | 0.11 | 0.334 | 0.01 | 0.958 |
# Hospitalizations | −0.16 | 0.253 | 0.16 | 0.244 |
Medication use (by target) | ||||
Dopaminergic | 2.40 | 0.018 | 2.10 | 0.037 |
Serotonergic | −0.10 | 0.924 | 2.61 | 0.010 |
Glutamatergic | −0.18 | 0.860 | −0.04 | 0.969 |
GABAergic | −0.81 | 0.417 | 1.46 | 0.146 |
Norepinephrinergic | 2.25 | 0.026 | 0.89 | 0.376 |
Lithium | −1.87 | 0.064 | 0.73 | 0.467 |
No medication | 0.99 | 0.325 | −0.74 | 0.458 |
# Meds | −0.12 | 0.153 | 0.14 | 0.090 |
Pearson correlations (for continuous measures) or t-tests (for categorical measures) were computed across all participants. A higher r value indicates a stronger association between brain (or behavioral) scores and disease severity, while a higher t value indicates higher brain (or behavioral) scores in participants taking the specific medication. Significant correlations or t-tests that survived FDR correction (q > 0.05) are indicated in bold. The same analysis was performed after classifying medication by medication class (see Table S3).